| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $200K | — | -51.3% |
| SG&A Expense | $514K | — | -65.6% |
| Operating Income | -$714K | — | +62.5% |
| Net Income | -$695K | — | +62.5% |
| EPS (Basic) | -$0.21 | — | +66.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.4M | -15.3% | -31.0% |
| Total Assets | $2.5M | -15.8% | -31.3% |
| Current Liabilities | $1.3M | +15.6% | +0.6% |
| Total Liabilities | $1.3M | +15.6% | +0.6% |
| Stockholders' Equity | $1.2M | -34.6% | -65.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$438K | — | +63.1% |
| Financing Cash Flow | $0 | — | -100.0% |